A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma

NCT04831658 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Primary Central Nervous System Lymphoma

Interventions

DRUG: the dose-escalation phase

Sponsor

Mingzhi Zhang